QUOTE AND NEWS
newratings.com  8 hrs ago  Comment 
PARIS (dpa-AFX) - Regeneron Pharmaceuticals, Inc. (REGN) and Sanofi announced that the U.S. Food and Drug Administration approved DUPIXENT or dupilumab Injection, the first and only biologic medicine approved for the treatment of adults with...
New York Times  Mar 28  Comment 
The drug makers Regeneron Pharmaceuticals and Sanofi made a rare move, negotiating with insurers in advance over the price for Dupixent.
newratings.com  Mar 27  Comment 
PARIS (dpa-AFX) - VIVUS, Inc. ( VVUS) announced Monday that it reached an agreement with French drug major Sanofi (SNY) to return the commercial rights for STENDRA in Africa, the Middle East, Turkey and the Commonwealth of Independent States,...
FiercePharma  Mar 27  Comment 
Sanofi reviews consumer health business media buying and planning account post-Boehringer swap beth.bulik Sun, 03/26/2017 - 21:02
Motley Fool  Mar 23  Comment 
Shares shot up 33% on Thursday, fueled by rumors that the company is about to accept a takeover bid.
FiercePharma  Mar 23  Comment 
Sanofi on verge of $1B-plus deal for arthritis-focused biotech Flexion: source aliu Thu, 03/23/2017 - 09:34
The Times of India  Mar 23  Comment 
PHARMACEUTICALS-EUROPE/FDA:Crunch week looms for Sanofi, Roche and GSK at U.S. drugs agency
FiercePharma  Mar 22  Comment 
Sanofi exec fires back amid fight over Zika vaccine license esagonowsky Wed, 03/22/2017 - 15:46
FiercePharma  Mar 21  Comment 
Sanofi, Regeneron ask court to shield Dupixent from Amgen patent attack tracy Tue, 03/21/2017 - 14:55
newratings.com  Mar 21  Comment 
PARIS (dpa-AFX) - Sanofi (SNYNF, SNY) said that its social experiment in 160 participants have shown that allergy sufferer's sleep could be disrupted nearly 4 times more than a normal person. The makers of Xyzal Allergy 24 HR said half of the...




Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki